Save information for later
Sign Up

Learn About Mast Cell Activation Syndrome (MCAS)

What is the definition of Mast Cell Activation Syndrome (MCAS)?
Mast cell activation syndrome (MCAS) causes a person to have repeated severe allergy symptoms affecting several body systems. In MCAS, mast cells mistakenly release too many chemical agents, resulting in symptoms in the skin, gastrointestinal tract, heart, respiratory, and neurologic systems. Mast cells are present throughout most of our bodies and secrete different chemicals during allergic reactions. Symptoms include episodes of abdominal pain, cramping, diarrhea, flushing, itching, wheezing, coughing, lightheadedness and rapid pulse and low blood pressure. Symptoms can start at any age, but usually begin in adulthood. The cause of MCAS is unknown. Diagnosis is based on the symptoms, clinical exam, and specific laboratory testing. Other conditions may need to be excluded before MCAS can be diagnosed.
What are the alternative names for Mast Cell Activation Syndrome (MCAS)?
  • Mast cell activation syndrome
  • MCAS
Who are the top Mast Cell Activation Syndrome (MCAS) Local Doctors?
Experienced in Mast Cell Activation Syndrome (MCAS)
Internal Medicine | Hospital Medicine
Experienced in Mast Cell Activation Syndrome (MCAS)
Internal Medicine | Hospital Medicine

South Sound Inpatient Physicians PLLC

407 14th Ave Se, 
Puyallup, WA 
 (0.5 mi)
Experience:
15+ years
Languages Spoken:
English

Syed Shah is a Hospital Medicine provider in Puyallup, Washington. Dr. Shah has been practicing medicine for over 15 years and is rated as an Experienced provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Arteriovenous Malformation, Liver Failure, End-Stage Renal Disease (ESRD), Gastrostomy, and Percutaneous Coronary Intervention (PCI).

Experienced in Mast Cell Activation Syndrome (MCAS)
Gastroenterology
Experienced in Mast Cell Activation Syndrome (MCAS)
Gastroenterology

Kaiser Foundation Health Plan Of Washington

301 S 320th St, 
Federal Way, WA 
 (9.1 mi)
Experience:
14+ years
Languages Spoken:
English, Hindi, Punjabi
Accepting New Patients
Offers Telehealth

Jagpal Klair is a Gastroenterologist in Federal Way, Washington. Dr. Klair has been practicing medicine for over 14 years and is rated as an Experienced provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Jaundice, Diarrhea, Gastrointestinal Bleeding, Endoscopy, and Colonoscopy. Dr. Klair is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Experienced in Mast Cell Activation Syndrome (MCAS)
Allergy and Immunology
Experienced in Mast Cell Activation Syndrome (MCAS)
Allergy and Immunology
9040 Jackson Ave, 
Tacoma, WA 
 (13.1 mi)
Languages Spoken:
English

Jeannie Bay is an Allergy and Immunologist in Tacoma, Washington. Dr. Bay and is rated as an Experienced provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). Her top areas of expertise are Mast Cell Activation Syndrome (MCAS) and Asthma.

What are the latest Mast Cell Activation Syndrome (MCAS) Clinical Trials?
An Open-label, Multicenter, Rollover Study in Patients Who Participated in an Avapritinib Clinical Study

Summary: The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 Study of Avapritinib in Combination With Decitabine in Patients With Systemic Mastocytosis With an Associated Hematologic Neoplasm (SM-AHN)

Summary: Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of t...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center